Guggenheim analyst Vamil Divan reiterated a Buy rating and $46.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).The analyst commented: "Unicycive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE